France Nucleic Acid Therapeutics Cdmo Market Size & Outlook
- HC Outsourcing
- Clinical & Non-Clinical Outsourcing Services
- Nucleic Acid Therapeutics CDMO Market Outlook
- Clinical & Non-Clinical Outsourcing Services
Global Market
Related Markets
Ask Prism AI anything about the nucleic acid therapeutics cdmo market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
France nucleic acid therapeutics cdmo market highlights
- The France nucleic acid therapeutics cdmo market generated a revenue of USD 605.3 million in 2025 and is expected to reach USD 1,754.0 million by 2033.
- The France market is expected to grow at a CAGR of 14.3% from 2026 to 2033.
- In terms of segment, rna-based therapies was the largest revenue generating type in 2025.
- RNA-based Therapies is the most lucrative type segment registering the fastest growth during the forecast period.
Nucleic acid therapeutics cdmo market data book summary
| Market revenue in 2025 | USD 605.3 million |
| Market revenue in 2033 | USD 1,754.0 million |
| Growth rate | 14.3% (CAGR from 2026 to 2033) |
| Largest segment | Rna-based therapies |
| Fastest growing segment | RNA-based Therapies |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | RNA-based Therapies, Gene Therapy |
| Key market players worldwide | Catalent Inc, Thermo Fisher Scientific Inc, Lonza Group Ltd, FUJIFILM Holdings Corp, Charles River Laboratories International Inc, Eurofins Scientific SE, PerkinElmer, Oxford Biomedical Research, Danaher Corp |
Other key industry trends
- In terms of revenue, France accounted for 3.5% of the global nucleic acid therapeutics cdmo market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, UK nucleic acid therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 3,101.3 million by 2033.
The France nucleic acid therapeutics CDMO market is driven by rising innovations in gene & RNA based therapy and increasing demand for outsourcing services. Moreover, specialized expertise and infrastructure, such as oncology centers, clinical investigation centers, and national clusters & networks, as well as clinical research centers, are driving the demand for nucleic acid therapeutics CDMOs in France.
In addition, the country lays emphasis on the need for innovative drugs, which is expected to create new drug demand, leading to market growth. This has led to an increase in innovations and investment, which is the key strategy implemented by the market to sustain the competitive edge, generating future revenue.
For instance, in September 2021, Flash Therapeutics, a France-based CDMO, announced 3-year funding to develop its Lenti Flash viral vector tech and to double its manufacturing capacity. It will allow the company for large-scale clinical batch production, including both integrative DNA and RNA technologies.
No credit card required*
Publish Date: Jun 10, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nucleic Acid Therapeutics CDMO Market Scope
Nucleic Acid Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| PerkinElmer | View profile | 10001+ | Waltham, Massachusetts, United States, North America | www.perkinelmer.com |
| Oxford Biomedical Research | View profile | 11-50 | Rochester Hills, Michigan, United States, North America | www.oxfordbiomed.com/ |
France Nucleic Acid Therapeutics CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Nucleic Acid Therapeutics CDMO Market Outlook will help companies and investors design strategic landscapes.
Rna-Based Therapies was the largest segment with a revenue share of 74.38% in 2025.
Horizon Databook has segmented the France nucleic acid therapeutics cdmo market based on rna-based therapies, gene therapy covering the revenue growth of each sub-segment from 2021 to 2033.
The France nucleic acid therapeutics CDMO market is driven by rising innovations in gene & RNA based therapy and increasing demand for outsourcing services. Moreover, specialized expertise and infrastructure, such as oncology centers, clinical investigation centers, and national clusters & networks, as well as clinical research centers, are driving the demand for nucleic acid therapeutics CDMOs in France.
In addition, the country lays emphasis on the need for innovative drugs, which is expected to create new drug demand, leading to market growth. This has led to an increase in innovations and investment, which is the key strategy implemented by the market to sustain the competitive edge, generating future revenue.
For instance, in September 2021, Flash Therapeutics, a France-based CDMO, announced 3-year funding to develop its Lenti Flash viral vector tech and to double its manufacturing capacity. It will allow the company for large-scale clinical batch production, including both integrative DNA and RNA technologies.
- France Nucleic Acid Therapeutics Cdmo Market Type Outlook (Revenue, USD Million , 2021-2033)
- Gene Therapy
- RNA-based Therapies
- France Nucleic Acid Therapeutics Cdmo Market Service Outlook (Revenue, USD Million , 2021-2033)
- Process Development and Optimization
- Manufacturing Services
- Analytical and Quality Control Services
- Others
- France Nucleic Acid Therapeutics Cdmo Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical Companies
- Government & Academic Research Institutes
- Biotech Companies
- France Nucleic Acid Therapeutics Cdmo Market Application Outlook (Revenue, USD Million , 2021-2033)
- Rare Diseases
- Genetic Disorders
- Infectious Diseases
- Others
Reasons to subscribe to Nucleic Acid Therapeutics CDMO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Nucleic Acid Therapeutics CDMO Market Outlook databook
- Our clientele includes a mix of Nucleic Acid Therapeutics CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France Nucleic Acid Therapeutics CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into France Nucleic Acid Therapeutics CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
France Nucleic Acid Therapeutics Cdmo Market, 2021-2033 (US$M)
France nucleic acid therapeutics cdmo market statistics, by type, 2021-2033 (US$M)
